Pluri (NASDAQ:PLUR) Trading 3.3% Higher – Should You Buy?

Pluri Inc. (NASDAQ:PLUR)’s share price shot up 3.3% on Friday . The company traded as high as $2.0093 and last traded at $1.86. 37,334 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 41,117 shares. The stock had previously closed at $1.80.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Pluri Price Performance

The business has a 50 day moving average of $2.31 and a 200 day moving average of $2.99. The firm has a market capitalization of $20.07 million, a price-to-earnings ratio of -0.41 and a beta of 0.64.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.11. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.66 million.

Institutional Trading of Pluri

A hedge fund recently bought a new position in Pluri stock. Jane Street Group LLC bought a new stake in shares of Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the SEC. Hedge funds and other institutional investors own 16.59% of the company’s stock.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.